To study the efficacy of Rifaximin (drug) vs Norfloxacin (drug) in liver disease
Phase 2
- Conditions
- Health Condition 1: K769- Liver disease, unspecified
- Registration Number
- CTRI/2023/12/060803
- Lead Sponsor
- Institute of Liver and Biliary Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1) Age >18 years
2) Cirrhosis (of any etiology) with ascites
3) Prior incident SBP
Exclusion Criteria
1.Allergy to norfloxacin or rifaximin
2.Recent history of upper gastrointestinal bleed (UGIB) within 2 weeks
3.Patients with a history of multiple episodes of SBP
4.Patients with inoperable or not treatable HCC or other non-hepatic malignancy
5.Patients on immunosuppression
6.HIV infected
7.Post liver transplant
8.Recent ( <6 months) abdominal surgery
9.Pregnant/lactating women
10.Other causes of ascites like tubercular or malignancy
11.Patients developing SBP on Norfloxcacin
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method